Suscribirse

Estimate of anti-SARS-CoV-2 spike IgG antibodies prevalence among Iranian population based on blood donations: A serial cross-sectional study during the third wave of the pandemic - 01/02/23

Doi : 10.1016/j.tracli.2022.09.003 
Fahimeh Ranjbar Kermani a, 1, Ali Arabkhazaeli a, 1, Peyman Eshghi b, Mahtab Maghsudlu a, , Sedigheh Amini-Kafiabad a, Amir Teimourpour a, Mahmoud Reza Pourkarim a, c, d
a Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran 
b Pediatric Congenital Hematologic Disorders, Research Institute for Children Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran 
c Health Policy Research Centre, Institute of Health, Shiraz University of Medical Sciences, P.O. Box 71348-45794, Shiraz 71348-54794, Iran 
d Laboratory for Clinical and Epidemiological Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium 

Corresponding author.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Objectives

Iran is one of the countries that have been confronted with the SARS-CoV-2 epidemic since February 2020. This study aimed to determine the levels of specific IgG antibodies against SARS-CoV-2 among healthy blood donors to estimate the burden of the epidemic.

Material and methods

A serial cross-sectional study was conducted on blood donors who referred to 31 main blood donation centers in different provinces during the third weeks of September, October, and November 2020. A questionnaire was filled out to collect socio-demographic characteristics, history of contact with COVID-19 patients, and history of COVID-19. A blood sample was collected from each participant to assess the antibodies against SARS-CoV-2 using the ELISA method. The crude prevalence of anti-SARS-CoV-2 IgG was calculated. Then it was weighted based on the gender and age groups of the general population in each province and adjusted for test sensitivity and specificity.

Results

During three time points of the study, 3840, 3697, and 3152 participants enrolled. The seroprevalence of SARS-CoV-2 IgG antibodies was 19.59% (17.18–22.00), 22.67% (20.70–24.65), and 32.63% (29.93–35.33) over the three rounds of the study.

We found an association between the seropositivity and the highest educational level; AOR 0.76 (0.63–0.93), history of close contact with COVID-19 patients; AOR 1.69 (1.35–2.11), and history of confirmed SARS-CoV-2 infection; AOR 8.86 (5.38–14.60).

Conclusion

This study showed that about one-third of the population had been infected with COVID-19. Furthermore, a significant upward trend in seroprevalence was observed. The predisposing factors indicate the importance of public health.

El texto completo de este artículo está disponible en PDF.

Keywords : SARS-CoV-2, Seroprevalence, Blood donors, Population, Cross-sectional, Iran


Esquema


© 2022  Société française de transfusion sanguine (SFTS). Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 30 - N° 1

P. 123-129 - février 2023 Regresar al número
Artículo precedente Artículo precedente
  • Blood-Type-A is a COVID-19 infection and hospitalization risk in a Turkish cohort
  • Meryem Cetin, Sirin Cetin, Ayse Ulgen, Wentian Li
| Artículo siguiente Artículo siguiente
  • Association of blood donor’s biological characteristics on outcomes of cardiac surgery patients receiving red blood cells transfusion
  • Vidushi Gupta, Gopal K. Patidar, Milind Hote, Radheshyam Mehar, Yashaswi Dhiman, Anjali Hazarika

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.